Fig. 1

Upregulated SRSF9 expression is associated with poor outcome in individuals with CRC. A qRT-PCR assay for detecting relative RNA levels of SRSF9 in CRC cell lines and an immortalized normal intestinal epithelial cell line (*p < 0.05; **p < 0.01; ***P < 0.001, Student’s t test). B Western blot assays were employed to detect SRSF9 protein levels in CRC cell lines and in an immortalized normal intestinal epithelial cell line (*p < 0.05; **p < 0.01; ***p < 0.001, Student’s t test). C SRSF9 mRNA levels were determined based on the TCGA database (p < 0.05, Wilcoxon test). D Representative IHC staining images of SRSF9 staining in CRC tissues and adjacent normal tissues (N: adjacent normal tissues; T: CRC tissues). Scale bar = 25 μm. E IHC scores of 63 pairs of CRC tissues based on SRSF9 staining (***p < 0.0001, Wilcoxon test). F Representative images showing SRSF9 expression in CRC tumors with different Dukes stages and with or without lymph node metastasis. High expression of SRSF9 was observed for stage C CRC tumors and those that showed positive lymph node metastasis, while low expression of SRSF9 was detected for stage A CRC tumors and those with negative lymph node metastasis (LN^neg: negative lymph node metastasis, LN^pos: positive lymph node metastasis). G Percentages of cases with high or low expression of SRSF9 according to various clinicopathological features (*p < 0.05, chi-squared test). H Survival analysis of CRC patients based on the GEO database (GSE17538) for the correlation between SRSF9 expression and overall survival (p < 0.01, log-rank test). Data are presented as the mean ± standard deviation of the values obtained in three independent experiments